LENSAR Inc. has published a new corporate presentation highlighting advancements in laser cataract surgery. The company reports a global market of approximately 32 million cataract procedures in 2025, with a significant unmet need for patients with treatable astigmatism. LENSAR's proprietary ALLY Robotic Cataract Laser System® is featured as a dual-modality, compact device designed to streamline procedures, offering time savings for both staff and patients. The presentation notes that regulatory approvals in the EU and Southeast Asia have expanded the company's addressable market. According to cited data, 60% of patients indicate a preference for robotic laser cataract surgery, associating it with feelings of calm, confidence, and assurance. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LENSAR Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.
Comments